OTC · BMYMP
Healthcare · Drug Manufacturers - General
$400.00
Down-$540.22 (-57.46%)
Updated Aug 31, 2026, 8:55 AM
SID Score
6.8/10
Composite research score
Smart Money
34/100
Bearish
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BMYMP does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BMYMP.
BMYMP research
Company profile and research snapshot.
BRISTOL-MYERS SQUIBB $2PR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Guggenheim | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 31, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
SeekingAlpha · Mar 24, 2026
AQRâs Q4 2025 13F: $191B portfolio led by Nvidia plus Apple, Microsoft, Alphabet & Amazon, with selective diversification. See more details here.
Yahoo · Mar 9, 2026
Bristol Myers wins FDA approval to expand Sotyktu for psoriatic arthritis after strong POETYK study data, adding a new indication for the TYK2 inhibitor.
Yahoo · Mar 9, 2026
The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs Revlimid and Pomalyst.
Yahoo · Mar 9, 2026
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Interpretive context generated from the platform’s current data sources.
Bristol-Myers Squibb's preferred convertible series 2 shares (BMYMP) currently trade at $400.00 per share, per SID market data. The security exhibits notably low volatility characteristics, registering a beta of just 0.3022 against the broader market, which is consistent with the defensive profile typical of preferred equity instruments in the healthcare sector. Average daily trading volume stands at approximately 5 shares, according to Massive/Polygon data, indicating extremely limited liquidity that presents material execution risk for investors seeking to build or exit positions. The thin trading volume suggests this preferred series is tightly held, with minimal secondary market activity. Despite the low float dynamics, the underlying Bristol-Myers Squibb entity carries a total market capitalization of approximately $1.82 trillion across all share classes, per SID market data. The low beta underscores the instrument's relative insulation from broader equity market fluctuations, aligning with its fixed-income-like characteristics.
Bristol-Myers Squibb's preferred convertible series 2 reflects underlying company valuation metrics that position the healthcare giant within reasonable bounds relative to sector peers. The price-to-earnings ratio stands at 17.28, according to SID market data, suggesting moderate earnings valuation for a large-cap pharmaceutical company. The PEG ratio of 0.896, per SEC filings data, falls below the 1.0 threshold commonly referenced as a benchmark for growth-adjusted value, indicating that the current earnings multiple may be justified relative to projected growth rates. The price-to-book ratio registers at 5.62, reflecting the premium typically associated with pharmaceutical intellectual property and pipeline assets. The dividend yield stands at approximately 4.84%, a meaningful income component that enhances total return potential for holders of this preferred convertible instrument. This yield level positions BMYMP competitively among income-generating healthcare securities in the current rate environment.
Smart money indicators for Bristol-Myers Squibb's preferred convertible series 2 reflect a bearish composite signal, with the overall smart money score registering at 34 out of 100, per SID market data. The institutional component contributes a moderate 13.0 out of 25 points, suggesting tepid but not absent institutional engagement. Dark pool activity scores 8.5 out of 25, according to SEC filings and alternative data sources, indicating below-average off-exchange positioning by large block traders. Congressional trading activity registers at 12 out of 25, reflecting middling legislative insider exposure. Notably, the insider trading component scores 0.0 out of 25, the lowest possible reading. According to SEC Form 4 filings, three insider transactions occurred within the last 90 days, comprising one purchase and two sales. The net selling pattern among insiders, with sells outnumbering buys two-to-one, aligns with the bearish overall smart money signal and suggests company executives are reducing their direct exposure to the equity at current price levels.
Bristol-Myers Squibb's preferred convertible series 2 derives its fundamental value from the parent company's earnings trajectory, though no recent earnings data is currently available for direct analysis, per company earnings reports. The existing valuation metrics provide indirect insight into the earnings framework: the trailing P/E ratio of 17.28 implies annualized earnings power supporting the current price level, according to SID market data. The PEG ratio of 0.896 suggests that analyst consensus growth estimates, when factored against the earnings multiple, indicate potential undervaluation relative to expected earnings expansion. As a preferred convertible instrument, BMYMP holders maintain a senior claim on earnings distributions relative to common shareholders, with the 4.84% dividend yield representing a contractual income obligation. Investors should monitor Bristol-Myers Squibb's upcoming quarterly earnings releases for updates on pharmaceutical pipeline progress, revenue trends from key therapeutic franchises, and any guidance revisions that could affect the conversion economics of this preferred series.
Wall Street coverage of Bristol-Myers Squibb reflects a modestly constructive consensus, with recent analyst activity skewing toward positive or neutral stances. According to Wall Street analyst reports, Argus Research upgraded its rating to Buy from Hold on August 5, 2026, representing the most notable recent shift in sentiment. Guggenheim and Truist Securities both reiterated Buy ratings on July 31, 2026, per SID consensus data, reinforcing the bullish contingent among covering analysts. Citigroup maintained its Neutral stance on August 3, 2026, while Wells Fargo reiterated an Equal-Weight rating on July 31, 2026, reflecting a more cautious segment of the coverage universe. Of the five most recent analyst actions, three carry Buy-equivalent ratings and two reflect neutral positioning, producing a 60% bullish skew in recent coverage activity. No analyst issued a Sell-equivalent rating in the current review period, suggesting that even the more conservative coverage views do not anticipate material downside from current levels.
The latest Smart Investors Daily articles mentioning BMYMP.
